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INTRODUCTION 27
Staphylococcus aureus bacteraemia (SAB) is a frequent infectious disease 28 worldwide, especially in healthcare settings; it is even a suspected negative 29 consequence of medical progress [1] [2] [3] . Annual incidences range from 30 approximately 10 to 40 per 100 000 persons [4, 5] . Recent reports indicate an 31 impact of patient-or population-level measures [6] . 32 33 Case-fatality rates dropped during the 20 th century [7] but most recent studies still 34 report 12 weeks case-fatality rates ranging from 18% to 32% [8, 9] , especially for 35 community-acquired SAB [5, 10] . Many prognostic factors associated with 36 mortality have been identified [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] and have been reviewed in detail [7] . 37
Advanced age and sepsis are the most consistent factors whereas comorbidities, 38 setting of acquisition and treatment (e.g. empirical and definitive antibiotics) are 39 subject to debate. 40 41 Adequate treatment requires SAB source control, appropriate intravenous 42 antibiotics and, for some patients, surgery and intensive care, but large areas of 43 uncertainty remain concerning clinical management [18] . No randomized 44 controlled trial has directly evaluated the relative performance of most frequently 45 used empirical antibiotics, like large-spectrum beta-lactams, specific 46 antistaphylococcal penicillins, glycopeptides and aminoglycosides [3] . Lyon, Montpellier, Nancy, Nîmes, Paris (Bichat-Claude Bernard) and Rennes. 55
Staphylococcus aureus endocarditis-specific analyses were described elsewhere 56 [19] [20] [21] . Standardized investigation of all cases was encouraged (e.g. follow-up 57 blood cultures and echocardiography) but was not mandatory. Our conclusions may be affected by a referral bias. Since some patients were 206 transferred to tertiary care centres, we may overestimate the case-fatality rate of 207 SAB. Follow-up was incomplete in 119/2091 patients (5.7%) who were younger 208 and had less comorbidities and complications. Therefore one can assume they were 209 less likely to die within 12 weeks. The main strengths of our study were the 210 multicentre recruitment, and the detailed prospective clinical data including 211 antibiotic treatment in a large cohort of patients. We preferred to analyse global 212 case-fatality at week 12 because diagnosis of disease-specific death is subject to Like in most other studies [8, 9, 11, 14, 17] , setting of acquisition was not 231 associated with prognosis of SAB in our cohort: community-acquired SAB was 232 associated with unknown primary focus (worse prognosis), whereas patients with 233 nosocomial SAB had more comorbidities (worse prognosis) and more catheter-234 related primary foci (better prognosis). 235
236
Endocarditis was no longer associated with prognosis after adjustment on mycotic 237 aneurism and complications like stroke and heart failure. Since the association of 238 endocarditis with increased mortality was moderate in bivariate analysis and on the 239 contrary lethal complications like stroke and heart failure also occur in non-240 endocarditis patients, we decided to maintain the latter in the multivariate model. 241
We may thus hypothesize that endocarditis without severe complications does not 242 worsen the prognosis of SAB. For the multivariate logistic regression: events to independent variables ratio is 55.6; age complied with linearity; we did not analyse interactions because none was expected, no collinearity was detected; Hosmer-Lemeshaw goodness-offit indicated a p-value of 0.618 and area under the curve for receiver operating characteristic was 0.807, which indicated a good fit to the real data. 
